Showing results (101-110 of 112) with videos related to
Sort By:
Pageof 12
Brain : a Journal of Neurology|August 1, 1986
Structural brain correlates of emotional disorder in multiple sclerosisP V Rabins, B R Brooks, P O'Donnell, et al.Journal of the Neurological Sciences|October 26, 2001
Quantitative assessment of motor fatigue in amyotrophic lateral sclerosisM Sanjak, J Brinkmann, D S Belden, et al.Annals of Neurology|April 1, 1983
Oligoclonal IgG bands in cerebrospinal fluid in various neurological diseasesA B Chu, J L Sever, D L Madden, et al.Neurology|October 27, 2004
Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trialB R Brooks, R A Thisted, S H Appel, et al.Neurology|April 28, 2004
Failure to detect enterovirus in the spinal cord of ALS patients using a sensitive RT-PCR methodW A Nix, M M Berger, M S Oberste, et al.Neurology|July 1, 1989
Linkage analysis in familial amyotrophic lateral sclerosisT Siddique, M A Pericak-Vance, B R Brooks, et al.Neurology|July 1, 1995
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, J A Cohen, et al.IARC Scientific Publications|January 1, 1988
Dosimeters of human exposure to carcinogens: polycyclic aromatic hydrocarbon-macromolecular adductsA Weston, J C Willey, D K Manchester, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2000
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, C C Ford, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|December 11, 2003
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trialK P Johnson, B R Brooks, C C Ford, et al.Pageof 12